Meglitinide analogues for type 2 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Black, Corri ^a   Donnelly, P ^b   McIntyre, L ^b   Royle, P L ^b   Shepherd, J P ^b   Thomas, S ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NONE

Author keywords

Benzamides therapeutic use ; Carbamates adverse effects; *therapeutic use ; Cyclohexanes adverse effects; *therapeutic use ; Diabetes mellitus, type 2 *drug therapy ; Hypoglycemic agents adverse effects; *therapeutic use

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; PLACEBO; REPAGLINIDE;

ABDOMINAL PAIN; ADRENAL TUMOR; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR SYMPTOM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; ERECTILE DYSFUNCTION; FACE EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GRAND MAL SEIZURE; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; JAUNDICE; KETOACIDOSIS; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PARESTHESIA; PRURITUS; QUALITY OF LIFE; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; THORAX PAIN; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 35448978003     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004654.pub2     Document Type: Review

References (97)

1. Bengel 2005 {published data only} Bengel FM, Abletshauser C, Neverve J, Schnell O, Nekolla SG, Standl E, Schwaiger M. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus - a randomized study using positron emission tomography. Diabetic Medicine 2005;22(2):158-63.
2. Chuang 1999 {published data only} Chuang L, Tai T, Juang JH, Chiang YD, Ki K, Jorgensen LN, Yeo LP. Effect of a prandial glucose regulator (NovoNorm) at two doses (0.5 mg and 2 mg) on glycemic control in type 2 diabetes in Taiwan. JAMA Southeast Asia 1999;15(1):22-5.
3. Derosa 2003 {published data only} Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice 2003;60(3):161-9.
4. Furlong 2002 {published data only} Furlong NJ, Hulme SA, O'Brien SV, Hardy KJ. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care 2002;25(10):1685-90.
5. Goldberg 1998 {published data only} Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, et al.A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21(11):1897-903.
6. Hanefeld 2000 {published data only} Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000;23(2):202-7.
7. Horton 2000 {published data only} Foley JE, Gatlin M, Dunn FL, Horton ES. Both nateglinide and metformin sustain HbA(1c) lowering over 52 weeks in drug-naive type 2 diabetes patients. Diabetologia 2003;44(Suppl 1):826.
8. Horton E, James F, Shen S, Baron M. Initial combination therapy (CT) with nateglinide and metformin is safe and effective. Diabetes 2003;52(Suppl 1):A448.
9. *Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23(11):1660-5.
10. Jovanovic 2000 {published data only} Jovanovic L, Dailey G, III, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. Journal of Clinical Pharmacology 2000;40(1):49-57.
11. Marre 2002 {published data only} Marre A, Van Gaal L, Usadel KH, Ball A, Whatmough I, Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obesity & Metabolism 2002;4(3):177-86.
12. Moses 1999 {published data only} Moses R. Repaglinide in combination therapy with metformin in Type 2 diabetes. Experimental & Clinical Endocrinology & Diabetes 1999;107(Suppl 4):S136-9.
13. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, et al.Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22(1):119-24.
14. Moses 2001 {published data only} Bech P, Moses R, Gomis R. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy-naive Type 2 diabetes: A placebo- controlled, multicentre study. Quality of Life Research 2003;12(4):413-25.
15. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001;24(1):11-5.
16. Raskin 2003 {published data only} Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, et al.Efficacy and Safety of Combination Therapy: Repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003;26(7):2063-8.
17. Rosenstock 2004 {published data only} Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, et al.Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27(6):1265-70.
18. Saloranta 2002 {published data only} Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. Journal of Clinical Endocrinology & Metabolism 2002;87(9):4171-6.
19. Van Gaal 2001 {published data only} Van Gaal LF, Van Acker KL, De Leeuw IH. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. Diabetes Research & Clinical Practice 2001;53(3):141-8.
20. Baron 2002 Baron MA, Mager RR, Vyas KH, Das Purkayastha D. Nateglinide (Starlix((R)) effectively lowers HbA(1c), through reductions in post prandial glucose in subjects with type 2 diabetes mellitus. Diabetes 2002;51(Suppl. 2):376.
21. Barone 2004 Barone M, Aiello A, Allochis G, Borzi V, Cannata E, Caronna S, et al.Repaglinide-metformin combination in the treatment of type 2 diabetes: Comparison between three different combination regimens. Diabetologia 2004;47(Suppl 1):A15.
22. Chen 2002 Chen YM, Zeng LY, Zhang GC, Jiang BQ, Qian XX. Clinical effects of repaglinide on type 2 diabetes mellitus. Chinese Journal of New Drugs and Clinical Remedies 2002;21(8):498-500.
23. Cozma 2002 Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 2002;25(8): 1271-6.
24. Damsbo 1999 Damsbo P, Marbury TC, Hatorp V, Clauson P, Muller PG. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. Diabetes Research & Clinical Practice Supplement 1999;45(1):31-9.
25. De Luis 2001 De Luis DA, Aller R, Cuellar L, Terroba C, Ovalle H, Izaola O, Romero E. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24(10):1844-5.
26. Foley 2001 Foley JE, Gatlin M, Dunn FL, Horton ES. Both nateglinide and metformin sustain HbA(1c) lowering over 52 weeks in drug-naive type 2 diabetes patients. Diabetologia 2001;44(Suppl 1):826.
27. Fujita 2001 Fujita T, Kosugi K, Ueda N, Hatano M. Oral nateglinide administration improves glycemic control of Type 2 diabetic patients, treated with intermediate-acting insulin. Diabetes 2001;50(Suppl 2):A435.
28. Hasslacher 2001 Hasslacher C, Koselj M, Gall MA, Sieber J, Dieken ML. Safety and efficacy of repaglinide in 281 type 2 diabetic patients with or without renal impairment. Diabetes 2001;50(Suppl 2):A116.
29. Hatorp 2002 Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics 2002;41(7):471-83.
30. Hirschberg 2000 Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000;23(3):349-53.
31. Hollander 2001 Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, et al.Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24(6):983-8.
32. Horton 2001 Horton ES, Gatlin M, Dunn FL, Foley JE. Risks/Benefits of achieving HbA1c goals with nateglinide. Diabetes 2001;50(Suppl 2):A438.
33. Horton 2003 Horton E, Foley J, Shen S, Baron M. Initial combination therapy with nateglinide and metformin is safe and effective. Diabetes 2003;Suppl 1:A448.
34. Hoyer 2000 Hoyer M, Mallows S. Nateglinide reduces mean glycemia in diet- and previously treated type 2 diabetic patients. Diabetes Research and Clinical Practice 2000;50(Suppl 1):S72.
35. Ishii 2001 Ishii T, Yamakita T, Yamagami K, Yamamoto T, Miyamoto M, Yoshioka K, et al.Nateglinide is safe and efficacious in lowering postprandial blood glucose in type 2 diabetic patients with various degree of renal function. Diabetes 2001;50(Suppl 2):A118.
36. Juhl 2000 Juhl CB, Porksen N, Hollingdal M, Sturis J, Pincus S, Veldhuis JD, et al.Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. Diabetes Care 2000;23(5):675-81.
37. Kahn 2001 Kahn SE, Montgomery B, Howell W, Ligueros SM, Hsu CH, Devineni D, et al.Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism 2001;86(12):5824-9.
38. Keilson 2000 Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism 2000;85(3):1081-6.
39. Khan 2000 Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Carrying Out or Commissioning Reviews. http://www.york.ac.uk/inst/crd/report4. htm 2000.
40. Lawrence 2005 Lawrence IG, Srinivasan BT, Tringham J, Jarvis J, Howe J, Skinner C, et al.Insulin treatment after 3 years in patients with type 2 diabetes following participation in a study of combination regimes of insulin, repaglinide and metformin. Diabetes 2005;54(Suppl 1):A513.
41. Ligueros-Saylan 2000 Ligueros-Saylan M, Khalilieh S, Lee J, Devineni D, Sunanda V, Zeig S, et al.Nateglinide has a low hypoglycemic potential in a missed-meal situation. Diabetes 2000;49:1511.
42. Mallows 2000 Mallows S, Guitard C. Nateglinide is effective and safe in elderly patients with Type 2 diabetes. Diabetes Research and Clinical Practice 2000;50(Suppl 1):S73.
43. Merz 2000 Merz M, Walter YH, Brookman L, Ma P, Gerich JE, Mcleod JF. Risk of delayed hypoglycemia is reduced with nateglinide compared to repaglinide. Diabetologia 2000;43(Suppl 1):714.
44. Mori 2001 Mori Y, Ishii H, Hikita M, Yokoyama J, Tajima N. The improvement of early phase of insulin secretion after glucose load with nateglinide in patients with type 2 diabetes. Diabetes 2001;50(Suppl 2):A127.
45. Nishimura 2002 Nishimura H, Shintani M, Maeda K, Okuda J, Tanaka S. Multiple effects of Nateglinide on glucose metabolism in obese patients with type 2 diabetes mellitus. Diabetes 2002;51:2528.
46. Owens 2000a Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000;23(4):518-23.
47. Owens 2000b Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000;23(4):518-23.
48. Rudovich 2002 Rudovich NN, Dieken MHL, Pfeiffer AFH. Comparison of effects of repaglinide and nateglinide on insulin secretion and postloading glucose excursions in patients with Type 2 diabetes. Diabetologia 2002;45:764.
49. Rudovich 2003 Rudovich N, Rochlitz H, Dieken ML, Pfeiffer A. Comparison of effects of repaglinide and nateglinide on insulin secretion and postloading glucose excursions in patients with type 2 diabetes. Diabetes 2003;52(Suppl 1):A454.
50. Saad 2002 Saad MF, Hale P, Khutoryansky N. Efficacy of repaglinide vs. nateglinide: As monotherapy or metformin combination therapy. Diabetes 2002;51:536.
51. Schmitz 2002 Schmitz O, Lund S, Andersen PH, Jonler M, Porksen N. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes Care 2002;25(2):342-6.
52. Schumacher 2001 Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, et al.Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. European Journal of Clinical Pharmacology 2001;57(2):147-52.
53. Schwartz 1998 Schwartz SL, Goldberg RB, Strange P. Repaglinide in type 2 diabetes: A randomized, double-blind, placebo-controlled, dose-response study. Diabetes 1998;47(Suppl 1):382.
54. Srinivasan 2005 Srinivasan BT, Lawrence IG, Tringham J, Jarvis J, Howe J, Skinner C, et al.3 year follow up of a randomised controlled trial of combination regimes of insulin, repaglinide and metformin in people with type 2 diabetes mellitus. Diabetes 2005;54(Suppl 1):A127.
55. Strange 1999 Strange P, Schwartz SL, Graf RJ, Polvino W, Weston I, Marbury TC, et al.Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. Diabetes Technology & Therapeutics 1999;1(3):247-56.
56. Tankova 2003 Saloranta C, Holmes D, Ball M, Dickinson S, Hershon K. Efficacy and safety of nateglinide in patients with mild hyperglycaemia. Diabetologia 2001;44 Suppl 1:A214.
57. Tankova T, Koev D, Dakovska L, Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Research and Clinical Practice 2003;59(1):43-9.
58. Torella 2002 Torella R, Lunetta M, Vitali L. Repaglinide plus bedtime insulin is as effective as premixed insulin twice daily but more safe than insulin alone in Type 2 diabetes mellitus inadequately controlled with oha therapy. Diabetologia 2002;45:765.
59. Walter 2000 Walter YH, Brookman L, Ma P, Gerich JE, Mcleod JF. Reduced risk of delayed hypoglycemia with nateglinide compared to repaglinide. Diabetes 2000;49(Suppl 1):521.
60. Wang 2004 Wang FN, Liao ZH, Yao B, Li YB, Hu GL, Weng JP. The impaired acute insulin response in newly diagnosed Type 2 diabetic patients can be restored by nateglinide and repaglinide. Diabetologia 2004;47(Suppl 1):A254.
61. Whitelaw 2000 Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus. Diabetic Medicine 2000;17(3):225-9.
62. Brogard 2000 *Brogard JM, Landin-Olsson M, Eriksson J. Repaglinide with bedtime insulin improves glycaemic control in poorly controlled type 2 diabetes. Diabetologia 2000;43:716.
63. Eriksson JG, Brogard JM, Landin-Olsson M, Clauson P, Rasmussen M. 1999, 48(Suppl):1575. The safety of repaglinide administered in combination with bedtime NPH-insulin in patients with type 2 diabetes. A randomized, semi-blinded, parallel-group, multi-centre trial. Diabetes 1999;48(Suppl):1575.
64. Landin-Olsson M, Brogard JMM, Eriksson J, Rasmussen M, Clauson P. A randomized, semi-blinded, parallel-group,multi-centre trial. Diabetes 1999, 48:0503. The efficacy of repaglinide administered in combination with bedtime NPH-insulin in patients with type 2 diabetes. A randomized, semi-blinded, parallel-group, multi-centre trial. Diabetes 1999;48:0503.
65. Davies 2002 *Davies MJ, Howe J, Jarvis J, Johnston V, Kitchener D, McNally PG, Lawrence IG. Use of the combination of insulin and the prandinal glucose regulator repaglinide in patients with type 2 diabetes mellitus. Diabetologia 2002;45(Suppl. 2):A265.
66. Davies MJ, Johnston V, Howe J, Kitchener D, Lawrence IG, McNally PG. Comparison of combination regimes of Insulin, Repaglinide and Metformin in type 2 diabetes: an interim analysis. Diabetic Medicine 2001;18(1 (Suppl.)):A43.
67. Howe J, Davies MJ, Johnston V, Kitchener D, McNally PG, Lawrence IG. Quality of life and treatment satisfaction with the combination of insulin, metformin and repaglinide in patients with Type 2 diabetes mellitus. Diabetic Medicine 2002;19(Suppl. 2):28-115.
68. Li 2005 Li JW, Tian HM, Li QF, Wang NZ, Wu T, Liu Y. Improvement of beta cell function by nateglinide and repaglinide in type 2 diabetic patients: a randomized controlled double blinded and double dummy multicentre study. Diabetologia 2005;48(Suppl. 1):A284.
69. Lund 2005 Lund SS, Tarnow L, Poulsen G, Frandsen M, Smidt U, Pedersen O, Parving HH, Vaag A. Effect of metformin vs repaglinide on postprandial glycaemia, plasma lipoproteins and free fatty acids in non-obese patients with type-2 diabetes (T2DM). Diabetologia 2005;48(Suppl. 1):A285.
70. Lund SS, Tarnow L, Poulsen G, Frandsen M, Smith UM, Pedersen O, Parving HH, Vaag A. Effect of metformin vs. repaglinide on glycaemic control and non-glycaemic cardiovascular risk-factors in non-obese patients with Type 2 diabetes mellitus (T2DM) uncontrolled by diet (The ReMet-study). Diabetologia 2004;45(Suppl. 1):A252.
71. Milenkovic 2005 Milenkovic T, Kozar-Markovic O, Percan V, Vesov G, Mitkova M, Kuzinovska N, Aleksovski B, Makrevska S, Kostojcinoska M, Neceva L, Mat R, Limani E, Kovacevska J. 20-week multicentre, prospective, open-label study of the efficacy, safety and applicability of repaglinide as a first line therapy in treating type 2 diabetes patients in Diabetes Centres in Macedonia [Bulgarian]. Endocrinologia 2005;10(1):28-34.
72. Panelo 2004 Panelo A, Wing JR. Similar improvement in glycemic control with lower risk of hypoglycemia with repaglinide and bedtime NPH insulin compared to twice dally NPH insulin. Diabetes 2004;53(Suppl. 2):A479.
73. Bastyr 2000 Bastyr EJ, Stuart CA, Brodows RG. Therapy focused on lowering postprandinal glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000;23:1236-41.
74. Bonora 2001 Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes. Diabetes Care 2001;24:2023-2029.
75. Breuer 2000 Breuer HWM. The postprandial blood glucose level. A new traget for optimising treatment of diabetes mellitus. Eur Heart J Supplements 2000;2 (supp D):D36-D37.
76. Cohen 1960 Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
77. DCCTRG 1993 The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine 1993;329(14):977-86.
78. De Fronzo 1999 De Fronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine 1999;131(4):281- 303.
79. de Vegt 1999 de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. Vol. 42, 1999:926-31.
80. DECODE 1999 DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnositc criteria. Lancet 1999;354:617-21.
81. Dornhurst 2001 Dornhurst A. Insulinotrophic meglitinide analogues. Lancet 2001;358:1709-16.
82. Gerich 2003 Gerich JE. Clinical significance, pathogenesis and management of postprandinal hyperglycaemia. Archives of Internal Medicine 2003;163:1306-16.
83. Hanefeld 1996 Hanefeld M, Fischer S, Schulze JJ, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11 year follow up. Diabetologia 1996;39:1577-83.
84. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002;21:1539-58.
85. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
86. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
87. Inzucchi 2002 Inzucchi SE. Oral antihyperglycaemic therapy for type 2 diabetes. JAMA 2002;287:360-72.
88. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
89. Khan 2000 Khan KS, ter Riet G, Glanville J, Sowden A, Kleijnen J. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out and commissioning reviews. 2000; Vol. CRD Report 4 (2nd edition).
90. Kirpichnikov 2002 Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Annal Internal Medicine 2002;137:25-33.
91. Landgraf 2000 Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs & Ageing 2000;17(5):411-25.
92. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408-12.
93. Shiba 2003 Shiba T. Improvement of insulin resistance by a new insulin secretagogue, nateglinide - analysis based on the homeostasis model. Diabetes Research and Clinical Practice 2003;62:87-94.
94. Stratton 2000 Stratton IM, Adler AI, Neil AW, et al.Association pf glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000;321:405-412.
95. UKPDS 1995 UK Prospective Diabetes Study Group. UK Prospective study 16: overview of 6 years therapy of type II diabetes - a progressive disease. Diabetes 1995;44:1249-58.
96. Watkins 2003 Watkins PJ. ABC of diabetes: Cardiovascular disease, hypertension, and lipids. BMJ 2003;326:874-6.
97. Yudkin 1994 Yudkin JS, Coppack S. Insulin resistance and impaired glucose tolerance. Lancet 1994;344:1294-5.